{| class="wikitable" style="text-align:center; width:100%;"
! colspan="2" style="color:white; font-size:125%; background-color:#08519c" align="center" |'''Page editor'''
! colspan="2" style="color:white; font-size:125%; background-color:#08519c" align="center" |'''Section editor'''
|-
| style="background-color:#F0F0F0; width:15%" |[[File:Ivy_Abraham.JPG|frameless|upright=0.3|center]]
| style="width:35%" |<big>[[User:Ivyabraham|Ivy Abraham, MD]]<br>Chicago, IL</big>
| style="background-color:#F0F0F0; width:15%" |[[File:nkv.jpg|frameless|upright=0.3|center]]
| style="width:35%" |<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
|-
|}
There is significant overlap between regimens for gastric cancer and '''[[esophageal cancer]]''', if you can't find the regimen you're looking for here, please try the esophageal cancer page. If you still can't find it, it is possible that we've moved it to the [[Gastric_cancer_-_historical|historical regimens page]].
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}

=Guidelines=
==CAP/ASCP/ASCO==
*'''2017:''' Bartley et al. [http://ascopubs.org/doi/full/10.1200/JCO.2016.69.4836 HER2 testing and clinical decision making in gastroesophageal adenocarcinoma] [https://www.ncbi.nlm.nih.gov/pubmed/28129524 PubMed]

==[http://www.esmo.org/ ESMO]==
*'''2016:''' Smyth et al. [https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Gastric-Cancer Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/27664260 PubMed]

==ESMO/ESSO/ESTRO==
*'''2013:''' Waddell et al. [https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdt344 Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up] [https://www.ncbi.nlm.nih.gov/pubmed/24078663 PubMed]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf NCCN Guidelines - Gastric Cancer]

=Neoadjuvant chemotherapy=
==Cisplatin & Fluorouracil {{#subobject:7b88be|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FP: '''<u>F</u>'''luorouracil & '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:c2dc1e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/13/1715.long Ychou et al. 2011 (ACCORD 07)]
| style="background-color:#1a9851" |Phase III (E)
|Surgery alone
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''This is the neoadjuvant portion of pre-planned "perioperative" therapy.''

''Study included patients with lower esophageal malignancy as well (25% gastric, 11% lower esophagus, and 64% GE junction).''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycle for 2 to 3 cycles'''
====Subsequent treatment====
*[[Surgery#Gastrectomy|Surgical resection]], then [[#Cisplatin_.26_Fluorouracil_2|adjuvant cisplatin & 5-FU]]

===References===
# '''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. [http://jco.ascopubs.org/content/29/13/1715.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444866 PubMed]

==ECF {{#subobject:f0281c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:66f602|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Surgery alone]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''This is the neoadjuvant portion of pre-planned perioperative therapy. In CRITICS, only patients with difficulties swallowing tablets were assigned to this treatment.''

''CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction'' 

''MAGIC included patients with lower esophageal malignancy as well (74% gastric, 14.8% lower esophagus, and 11.2% GE junction).''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

====Supportive medications====
*MAGIC, suggested as thrombosis prophylaxis:
**[[Warfarin (Coumadin)]] 1 mg PO once per day

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*MAGIC: [[Surgery#Gastrectomy|Surgical resection]] is performed 3 to 6 weeks after the completion of cycle 3, followed in 6 to 12 weeks by [[#ECF_2|adjuvant ECF]]
*CRITICS: [[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection, then adjuvant [[#ECF_2|ECF]] versus capecitabine, cisplatin, RT

===References===
# '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa055531 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16822992 PubMed]
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==ECX {{#subobject:c8ab0e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:27f848|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection, then adjuvant [[#ECX_2|ECX]] versus capecitabine, cisplatin, RT

===References===
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==EOF {{#subobject:139705|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOF: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>F</u>'''luourouracil
===Regimen {{#subobject:bf7464|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection, then adjuvant [[#EOF_2|EOF]] versus capecitabine, cisplatin, RT

===References===
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==EOX {{#subobject:86ee8e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOX: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:edae45|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''CRITICS trial included few patients with GE junction malignancy: 83% gastric, 17% GE junction''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day

'''21-day cycle for 3 cycles'''
====Subsequent treatment====
*[[Surgery#Gastrectomy|Surgery]] with a D1+ lymph node resection, then adjuvant [[#EOX_2|EOX]] versus capecitabine, cisplatin, RT

===References===
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==FLOT {{#subobject:aa7f4f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FLOT: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin, '''<u>T</u>'''axotere (Docetaxel)
===Regimen {{#subobject:16408e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext Al-Batran et al. 2016 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase II/III (E)
|ECF/ECX [[Complex_multipart_regimens#FLOT4-AIO|See link]]
|Superior OS (*) [[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the neoadjuvant portion of pre-planned perioperative chemotherapy. Reported efficacy is based on the phase III portion, which is not yet published other than in abstract form.''

====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on day 1
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1

'''14-day cycle for 4 cycles'''
====Subsequent treatment====
*[[Surgery#Gastrectomy|Surgery]], then [[#FLOT_2|adjuvant FLOT]]
===References===
# '''FLOT4-AIO:''' Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. Epub 2016 Oct 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27776843 PubMed]
## '''Update: Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==No neoadjuvant therapy==
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020693/ Schuhmacher et al. 2010 (EORTC 40954)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin, 5-FU, Folinic acid
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No antineoplastic treatment prior to surgery.''
====Subsequent treatment====
*[[Surgery#Gastrectomy|Surgery]]
===References===
# '''EORTC 40954:''' Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010 Dec 10;28(35):5210-8. Epub 2010 Nov 8. [http://ascopubs.org/doi/10.1200/JCO.2009.26.6114 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020693/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/21060024 PubMed]

=Adjuvant therapy=

==5-FU & Leucovorin, then 5-FU, Leucovorin, RT, then 5-FU & Leucovorin {{#subobject:2cd29|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FULV & RT: 5-'''<u>F</u>'''luoro'''<u>U</u>'''racil, '''<u>L</u>'''euco'''<u>V</u>'''orin (Folinic acid), '''<u>R</u>'''adiation '''<u>T</u>'''herapy
===Regimen {{#subobject:dfd3ec|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa010187 Macdonald et al. 2001 (INT-0116)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Surgery alone]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678342/ Fuchs et al. 2017 (CALGB 80101)]
| style="background-color:#1a9851" |Phase III (C)
|ECF, then FULV & RT, then ECF
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Treatment is to start 20 to 40 days after surgery.''

''Study included patients with GE junction malignancy as well (20% GE junction) and included patients with a performance status of 2.'' 
====Preceding treatment====
*INT-0116: [[Surgery#Gastrectomy|Surgery]] with R0 resection (10% underwent D2 dissection, 36% underwent D1 dissection and 54% underwent D0 dissection)
*CALGB 80101: [[Surgery#Gastrectomy|Surgery]]
====Chemotherapy, part 1====
*[[Fluorouracil (5-FU)]] 425 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5

'''28-day cycle for 1 cycle, followed by:'''

====Chemoradiotherapy====
*[[Fluorouracil (5-FU)]] 400mg/m<sup>2</sup> IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 4 and the last 3 days of radiation therapy
*Concurrent [[External_beam_radiotherapy|radiation therapy]] starting on day 1 with 180 cGy, 5 days per week; 25 fractions given over 5 weeks for a total of 4500 cGy

'''35-day course, followed by:'''

====Chemotherapy, part 2 (given 1 month after the completion of radiotherapy)====
*[[Fluorouracil (5-FU)]] 425 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5
*[[Folinic acid (Leucovorin)]] 20 mg/m<sup>2</sup> IV bolus once per day on days 1 to 5

'''28-day cycle for 2 cycles'''
===References===
# '''INT-0116:''' Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. [https://www.nejm.org/doi/full/10.1056/NEJMoa010187 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11547741 PubMed]
## '''Update:''' Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Epub 2012 May 14. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.7136 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517071/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22585691 PubMed]
# '''CALGB 80101:''' Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance). J Clin Oncol. 2017 Nov 10;35(32):3671-3677. Epub 2017 Oct 4. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.2130 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678342/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28976791 PubMed]

==CapeOx {{#subobject:cf9acc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CapeOX: '''<u>Cape</u>'''citabine & '''<u>OX</u>'''aliplatin
===Regimen {{#subobject:1ef938|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61873-4/fulltext Bang et al. 2012 (CLASSIC)]
| style="background-color:#1a9851" |Phase III (E)
|Surgery alone
| style="background-color:#1a9850" |Superior OS (*)
|-
|}
''Note: Reported efficacy is based on the 2014 update.''
====Preceding treatment====
*[[Surgery#Gastrectomy|Gastrectomy]] with D2 dissection
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for 8 cycles'''

===References===
# '''CLASSIC:''' Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. Epub 2012 Jan 7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61873-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22226517 PubMed]
## '''Update:''' Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1389-96. Epub 2014 Oct 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70473-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25439693 PubMed]

==Cisplatin & Fluorouracil {{#subobject:7b88be|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c2dc1e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/29/13/1715.long Ychou et al. 2011 (ACCORD 07)]
| style="background-color:#1a9851" |Phase III (E)
|Surgery alone
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''This is the adjuvant portion of pre-planned "perioperative" therapy. ''

''Study included patients with lower esophageal malignancy as well (25% gastric, 11% lower esophagus, and 64% GE junction).''
====Preceding treatment====
*[[#Cisplatin_.26_Fluorouracil|Neoadjuvant cisplatin & 5-FU]], then [[Surgery#Gastrectomy|surgery]]
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 28
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycle for 3 to 4 cycles, for a total of 6 cycles'''

===References===
# '''ACCORD 07:''' Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011 May 1;29(13):1715-21. [http://jco.ascopubs.org/content/29/13/1715.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21444866 PubMed]

==CX {{#subobject:4896bc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
<br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:877085|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/3/268.full Lee et al. 2011 (ARTIST)]
| style="background-color:#1a9851" |Phase III (C)
|XP, then RT, then XP
| style="background-color:#fee08b" |Might have inferior DFS
|-
|}
''Note: to our knowledge, this regimen was not tested as an experimental arm in an RCT prior to becoming a standard comparator arm.''
====Preceding treatment====
*R0 [[Surgery#Gastrectomy|gastrectomy]] and at least D2 dissection

====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for 6 cycles'''

===References===
# '''ARTIST:''' Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, Lim HY, Choi MG, Sohn TS, Noh JH, Bae JM, Ahn YC, Sohn I, Jung SH, Park CK, Kim KM, Kang WK. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012 Jan 20;30(3):268-73. Epub 2011 Dec 19. [http://jco.ascopubs.org/content/30/3/268.full link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22184384 PubMed]
## '''Update:''' Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, Sohn I, Jung SH, Choi MG, Lee JH, Bae JM, Kim S, Kim ST, Park JO, Park YS, Lim HY, Kang WK. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: Final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015 Oct 1;33(28):3130-6. Epub 2015 Jan 5. [http://jco.ascopubs.org/content/33/28/3130.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25559811 PubMed]

==ECF {{#subobject:f0281c|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:66f602|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Surgery alone]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#1a9851" |Phase III (C)
|CX & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''This is the adjuvant portion of pre-planned "perioperative" therapy. In CRITICS, only patients with trouble swallowing pills were assigned to this treatment arm.''

''MAGIC included patients with lower esophageal malignancy (74% gastric, 14.8% lower esophagus, and 11.2% GE junction).''

====Preceding treatment====
*[[#ECF|Neoadjuvant ECF]] x 3, then [[Surgery#Gastrectomy|surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

====Supportive medications====
*MAGIC, suggested as thrombosis prophylaxis:
**[[Warfarin (Coumadin)]] 1 mg PO once per day

'''21-day cycle for 3 cycles'''

===References===
# '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa055531 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16822992 PubMed]
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==ECX {{#subobject:4be711|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:af32a3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#1a9851" |Phase III (C)
|CX & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[#ECX|ECX]] x 3, then [[Surgery#Gastrectomy|surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for 3 cycles'''

===References===
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==EOF {{#subobject:46c9e7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOF: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:415ab0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#1a9851" |Phase III (C)
|CX & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Only patients with trouble swallowing pills were assigned to this treatment arm.''
====Preceding treatment====
*[[#EOF|EOF]] x 3, then [[Surgery#Gastrectomy|surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''21-day cycle for 3 cycles'''

===References===
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==EOX {{#subobject:64769a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
EOX: '''<u>E</u>'''pirubicin, '''<u>O</u>'''xaliplatin, '''<u>X</u>'''eloda (Capecitabine)
===Regimen {{#subobject:996244|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext Cats et al. 2018 (CRITICS)]
| style="background-color:#1a9851" |Phase III (C)
|CX & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*[[#EOX|EOX]] x 3, then [[Surgery#Gastrectomy|surgery]]
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day

'''21-day cycle for 3 cycles'''

===References===
# '''CRITICS:''' Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):616-628. Epub 2018 Apr 9. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30132-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29650363 PubMed]

==FLOT {{#subobject:3ad093|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FLOT: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin, '''<u>T</u>'''axotere (Docetaxel)
===Regimen {{#subobject:e6d646|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext Al-Batran et al. 2016 (FLOT4-AIO)]
| style="background-color:#1a9851" |Phase II/III (E)
|ECF/ECX [[Complex_multipart_regimens#FLOT4-AIO|See link]]
|Superior OS (*) [[Complex_multipart_regimens#FLOT4-AIO|See link]]
|-
|}
''This is the adjuvant portion of pre-planned perioperative chemotherapy. Reported efficacy is based on the phase III portion, which is not yet published other than in abstract form.''
====Preceding treatment====
*[[#FLOT|Neoadjuvant FLOT]] x 4, then [[Surgery#Gastrectomy|surgery]]
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on day 1
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV once on day 1
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV once on day 1
*[[Docetaxel (Taxotere)]] 50 mg/m<sup>2</sup> IV once on day 1

'''14-day cycle for 4 cycles'''

===References===
# '''FLOT4-AIO:''' Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. Epub 2016 Oct 22. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30531-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27776843 PubMed]
## '''Update: Abstract:''' Salah-Eddin Al-Batran, Nils Homann, Harald Schmalenberg, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Wolff H. Schmiegel, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Peter C. Thuss-Patience, Wolfgang Fischbach, Jorg Trojan, Michael Koenigsmann, Claudia Pauligk, Thorsten Oliver Goetze, Elke Jaeger, Johannes Meiler, Martin H. Schuler, and Ralf Hofheinz. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. Journal of Clinical Oncology 2017 35:15_suppl, 4004-4004 [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4004 link to abstract]

==FP, then Capecitabine & RT, then FP {{#subobject:778727|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
FP, then Capecitabine & RT, then FP: '''<u>F</u>'''luorouracil & '''<u>P</u>'''latinol (Cisplatin), followed by Capecitabine & '''<u>R</u>'''adiation '''<u>T</u>'''herapy, followed by '''<u>F</u>'''luorouracil & '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:20ea7f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066094/ Lee et al. 2006]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the primary reference, some guidelines list this regimen without FP cycles 1, 3, 4, 5. Dosage of [[Capecitabine (Xeloda)]] was listed as 625 to 825 mg/m<sup>2</sup> PO twice per day on days 1 to 5 or 1 to 7 while radiation is being given.'' 
====Preceding treatment====
*[[Surgery#Gastrectomy|Surgery]], 3 weeks prior
====Chemotherapy, part 1====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)

'''21-day cycle, followed immediately by:'''

====Chemoradiotherapy====
*[[Capecitabine (Xeloda)]] 825 mg/m<sup>2</sup> PO twice per day
*Concurrent [[External_beam_radiotherapy|radiation therapy]], 1.8 Gy fractions x 25 fractions given 5 days per week, for a total dose of 45 Gy

'''5-week course, followed 4 weeks later by:'''

====Chemotherapy, part 2====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 5000 mg/m<sup>2</sup>)

'''21-day cycle for 3 cycles'''

===References===
# Lee HS, Choi Y, Hur WJ, Kim HJ, Kwon HC, Kim SH, Kim JS, Lee JH, Jung GJ, Kim MC. Pilot study of postoperative adjuvant chemoradiation for advanced gastric cancer: adjuvant 5-FU/cisplatin and chemoradiation with capecitabine. World J Gastroenterol. 2006 Jan 28;12(4):603-7. [http://www.wjgnet.com/1007-9327/full/v12/i4/603.htm link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4066094/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/16489675 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(89)91607-3/fulltext Allum et al. 1989]
| style="background-color:#1a9851" |Phase III (C)
|[[Gastric_cancer_-_historical#Fluorouracil_.26_Mitomycin|5-FU & Mitomycin]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1990.8.8.1362 Coombes et al. 1990]
| style="background-color:#1a9851" |Phase III (C)
|FAM
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)92464-3/fulltext Hallissey et al. 1994]
| style="background-color:#1a9851" |Phase III (C)
|1. FAM<br> 2. Radiation
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.11.2757 Lise et al. 1995 (EORTC 40813)]
| style="background-color:#1a9851" |Phase III (C)
|FAM2
| style="background-color:#fee08b" |Might have inferior DFS
|-
|[https://link.springer.com/article/10.1007/BF02307081 Macdonald et al. 1995]
| style="background-color:#1a9851" |Phase III (C)
|FAM
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)01048-X/fulltext Nakajima et al. 1999 (JCOG8801)]
| style="background-color:#1a9851" |Phase III (C)
|5-FU & Mitomycin, then UFT
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.12.3810 Cirera et al. 1999]
| style="background-color:#1a9851" |Phase III (C)
|Mitomycin & Tegafur
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa010187 Macdonald et al. 2001 (INT-0116)]
| style="background-color:#1a9851" |Phase III (C)
|[[#5-FU_.26_Leucovorin.2C_then_5-FU.2C_Leucovorin.2C_RT.2C_then_5-FU_.26_Leucovorin|FULV & RT]]
| style="background-color:#d73027" |Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2003.06.103 Nashimoto et al. 2003 (JCOG 9206-1)]
| style="background-color:#1a9851" |Phase III (C)
|5-FU, Ara-C, Mitomycin, then 5-FU
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/16/9/1488/180180 Bouché et al. 2005 (FFCD 8801)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_Fluorouracil_2|Cisplatin & 5-FU]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa055531 Cunningham et al. 2006 (MAGIC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#ECF_2|ECF]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://academic.oup.com/annonc/article/18/8/1354/178453 De Vita et al. 2007 (GOIM 9602)]
| style="background-color:#1a9851" |Phase III (C)
|ELFE
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa072252 Sakuramoto et al. 2007 (ACTS-GC)]
| style="background-color:#1a9851" |Phase III (C)
|[[#S-1_monotherapy|S-1]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://academic.oup.com/jnci/article/100/6/388/997958 Di Costanzo et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|PELF
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.karger.com/Article/Abstract/292360 Kulig et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|EAP
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://link.springer.com/article/10.1007%2Fs10120-011-0027-3 Miyashiro et al. 2011 (JCOG 9206-2)]
| style="background-color:#1a9851" |Phase III (C)
|IV/IP Cisplatin, then UFT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No further treatment after surgery.''
====Preceding treatment====
*[[Surgery#Gastrectomy|Surgery]], with varying requirements for level of dissection (see papers for details)

===References===
# Allum WH, Hallissey MT, Kelly KA; British Stomach Cancer Group. Adjuvant chemotherapy in operable gastric cancer: 5 year follow-up of first British Stomach Cancer Group trial. Lancet. 1989 Mar 18;1(8638):571-4. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(89)91607-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2564109 PubMed]
# Coombes RC, Schein PS, Chilvers CE, Wils J, Beretta G, Bliss JM, Rutten A, Amadori D, Cortes-Funes H, Villar-Grimalt A, McArdle C, Rauschecker HF, Boven E, Vassilopoulos P, Welvaart K, Pinto Ferreira E, Wiig J, Gisselbrecht C, Rougier P, Woods EMA; International Collaborative Cancer Group. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. J Clin Oncol. 1990 Aug;8(8):1362-9. [http://ascopubs.org/doi/abs/10.1200/JCO.1990.8.8.1362 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2199622 PubMed]
# Hallissey MT, Dunn JA, Ward LC, Allum WH; British Stomach Cancer Group. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet. 1994 May 28;343(8909):1309-12. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)92464-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7910321 PubMed]
# '''EORTC 40813:''' Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Dos Santos JG, Labianca R, Rougier P, Gignoux M. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. J Clin Oncol. 1995 Nov;13(11):2757-63. [http://ascopubs.org/doi/abs/10.1200/JCO.1995.13.11.2757 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7595735 PubMed]
# Macdonald JS, Fleming TR, Peterson RF, Berenberg JL, McClure S, Chapman RA, Eyre HJ, Solanki D, Cruz AB Jr, Gagliano R, et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study. Ann Surg Oncol. 1995 Nov;2(6):488-94. [https://link.springer.com/article/10.1007/BF02307081 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8591078 PubMed]
# '''JCOG8801:''' Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, Goto M; Gastric Cancer Surgical Study Group. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet. 1999 Jul 24;354(9175):273-7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)01048-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10440302 PubMed]
# Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa A, Jolis L, Saigí E, Guasch I, Badia A, Boleda M. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer. J Clin Oncol. 1999 Dec;17(12):3810-5. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.12.3810 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10577853 PubMed]
# '''INT-0116:''' Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. [https://www.nejm.org/doi/full/10.1056/NEJMoa010187 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11547741 PubMed]
## '''Update:''' Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012 Jul 1;30(19):2327-33. Epub 2012 May 14. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.7136 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517071/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22585691 PubMed]
# '''JCOG 9206-1:''' Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S; Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003 Jun 15;21(12):2282-7. [http://ascopubs.org/doi/full/10.1200/JCO.2003.06.103 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12805327 PubMed]
# '''FFCD 8801:''' Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P; Fédération Francophone de Cancérologie Digestive Group. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005 Sep;16(9):1488-97. Epub 2005 Jun 6. [https://academic.oup.com/annonc/article/16/9/1488/180180 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15939717 PubMed]
# '''MAGIC:''' Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. [https://www.nejm.org/doi/full/10.1056/NEJMoa055531 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16822992 PubMed]
# '''GOIM 9602:''' De Vita F, Giuliani F, Orditura M, Maiello E, Galizia G, Di Martino N, Montemurro F, Cartenì G, Manzione L, Romito S, Gebbia V, Ciardiello F, Catalano G, Colucci G; Gruppo Oncologico Italia Meridionale. Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Ann Oncol. 2007 Aug;18(8):1354-8. Epub 2007 May 24. [https://academic.oup.com/annonc/article/18/8/1354/178453 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17525087 PubMed]
# '''ACTS-GC:''' Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977. [https://www.nejm.org/doi/full/10.1056/NEJMoa072252 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17978289 PubMed]
## '''Update:''' Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. Epub 2011 Oct 17. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.5908 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22010012 PubMed]
# Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008 Mar 19;100(6):388-98. Epub 2008 Mar 11. [https://academic.oup.com/jnci/article/100/6/388/997958 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18334706 PubMed]
# Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T, Dadan J, Drews M, Jeziorski A, Krawczyk M, Starzynska T, Wallner G. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology. 2010;78(1):54-61. Epub 2010 Mar 6. [https://www.karger.com/Article/Abstract/292360 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20215786 PubMed]
# '''JCOG 9206-2:''' Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O, Arai K; Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group. Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer. 2011 Aug;14(3):212-8. Epub 2011 Feb 19. [https://link.springer.com/article/10.1007%2Fs10120-011-0027-3 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21336855 PubMed]

==S-1 monotherapy {{#subobject:ec10ef|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, BSA-based {{#subobject:5dbc53|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70025-7/fulltext Tsuburaya (SAMIT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. Paclitaxel, then S-1<br> 2. Paclitaxel, then UFT
| style="background-color:#ffffbf" |Seems not superior
|-
|3. UFT
| style="background-color:#1a9850" |Superior DFS
|-
|}
====Preceding treatment====
*R0 or R1 [[Surgery#Gastrectomy|gastrectomy]] with at least D2 dissection, within 2 to 8 weeks
====Chemotherapy====
*[[Tegafur, gimeracil, oteracil (S-1)]] 80 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for 16 cycles (48 weeks)'''

===Variant #2, weight-based {{#subobject:0ee98c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa072252 Sakuramoto et al. 2007 (ACTS-GC)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Preceding treatment====
*R0 [[Surgery#Gastrectomy|gastrectomy]] with at least D2 dissection, within 6 weeks
====Chemotherapy====
*[[Tegafur, gimeracil, oteracil (S-1)]] as follows:
**BSA less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 28
**BSA between 1.25 and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 28
**BSA 1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 28

'''42-day cycles for one year'''
===References===
# '''ACTS-GC:''' Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977. [https://www.nejm.org/doi/full/10.1056/NEJMoa072252 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17978289 PubMed]
## '''Update:''' Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. Epub 2011 Oct 17. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.5908 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22010012 PubMed]
# '''SAMIT:''' Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014 Jul;15(8):886-93. Epub 2014 Jun 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70025-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24954805 PubMed]

=Metastatic or locally advanced disease, first-line=
==Capecitabine monotherapy {{#subobject:a9eb0b|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
X: '''<u>X</u>'''eloda (Capecitabine)
===Variant #1, 2000 mg/m<sup>2</sup>/day {{#subobject:b6ba4c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.geriatriconcology.net/article/S1879-4068(17)30022-X/fulltext Hwang et al. 2017]
| style="background-color:#1a9851" |Phase III (C)
|[[#CapeOx_2|XELOX]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycles'''

===Variant #2, 2500 mg/m<sup>2</sup>/day {{#subobject:b6ba4c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://annonc.oxfordjournals.org/content/15/9/1344.long Hong et al. 2004]
| style="background-color:#91cf61" |Phase II
|-
|}
''Study only included patients with Karnofsky status of at least 70%''
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for up to 6 cycles'''

===References===
# Hong YS, Song SY, Lee SI, Chung HC, Choi SH, Noh SH, Park JN, Han JY, Kang JH, Lee KS, Cho JY. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol. 2004 Sep;15(9):1344-7. [http://annonc.oxfordjournals.org/content/15/9/1344.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15319239 PubMed]
# Hwang IG, Ji JH, Kang JH, Lee HR, Lee HY, Chi KC, Park SW, Lee SJ, Kim ST, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017 May;8(3):170-175. Epub 2017 Jan 21. [https://www.geriatriconcology.net/article/S1879-4068(17)30022-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28119041 PubMed]

==CapeOx {{#subobject:4e3bb4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CapeOX: '''<u>Cape</u>'''citabine & '''<u>OX</u>'''aliplatin
===Regimen {{#subobject:4faee3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://academic.oup.com/annonc/article/17/1/29/161212 Jatoi et al. 2006]
| style="background-color:#91cf61" |Phase II
|-
|}
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 850 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Oxaliplatin (Eloxatin)]] 130 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Jatoi A, Murphy BR, Foster NR, Nikcevich DA, Alberts SR, Knost JA, Fitch TR, Rowland KM Jr; North Central Cancer Treatment Group. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006 Jan;17(1):29-34. Epub 2005 Nov 22. [https://academic.oup.com/annonc/article/17/1/29/161212 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16303863 PubMed]

==Carboplatin & Paclitaxel {{#subobject:4df570|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9725d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/9427274 Philip et al. 1997]
| style="background-color:#91cf61" |Phase II
|-
|[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2003&issue=02000&article=00008&type=abstract Gadgeel et al. 2003]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the original reference, some guidelines list the dosage of carboplatin as AUC 6.''

''Philip et al. included patients with locally advanced metastatic or recurrent esophageal or gastric cancer''

''Gadgeel et al. study showed an ORR of 35%''  
====Chemotherapy====
*[[Carboplatin (Paraplatin)]] AUC 5 IV once on day 1, '''given second'''
*[[Paclitaxel (Taxol)]] 200 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given first'''

'''21-day cycles'''

===References===
# Philip PA, Zalupski MM, Gadgeel S, Hussain M, Shields A. A phase II study of carboplatin and paclitaxel in the treatment of patients with advanced esophageal and gastric cancer. Semin Oncol. 1997 Dec;24(6 Suppl 19):S19-86-S19-88. '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9427274 PubMed]
# Gadgeel SM, Shields AF, Heilbrun LK, Labadidi S, Zalupski M, Chaplen R, Philip PA. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol. 2003 Feb;26(1):37-41. [http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2003&issue=02000&article=00008&type=abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12576922 PubMed]

==Cisplatin & Docetaxel {{#subobject:724868|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
DC: '''<u>D</u>'''ocetaxel, '''<u>C</u>'''isplatin
<br>TC: '''<u>T</u>'''axotere (Docetaxel), '''<u>C</u>'''isplatin

===Variant #1 {{#subobject:cd0910|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/25/22/3217.long Roth et al. 2007]
| rowspan="2" style="background-color:#1a9851" |Randomized Phase II (E)
|1. [[#ECF_3|ECF]]
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[#DCF|TCF]]
| style="background-color:#fee08b" |Might have inferior ORR
|-
|}
''Note: the protocol was amended to change the original dose of docetaxel from 85 mg/m<sup>2</sup> to 75 mg/m<sup>2</sup> based on high incidence of febrile neutropenia.''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 4 hours once on day 1

====Supportive medications====
*3 liters per day "hyperhydration"
*[[Dexamethasone (Decadron)]] 8 mg PO given 12 hours & 6 hours before [[Docetaxel (Taxotere)]], then 8 mg PO twice per day for 4 days after [[Docetaxel (Taxotere)]]
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis
*Growth factor support allowed, such as with [[Filgrastim (Neupogen)]]

'''21-day cycle for up to 8 cycles'''

===Variant #2 {{#subobject:f1913d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/23/24/5660.long Ajani et al. 2005 (V-325)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#DCF|DCF]]
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|}
''Patients: 100% adenocarcinoma histology (32% esophagogastric junction/fundus and 68% gastric antrum/body). 95% were metastatic. 1% with Karnofsky PS score of 70.'' 

====Chemotherapy====
*[[Docetaxel (Taxotere)]] 85 mg/m<sup>2</sup> IV over 60 minutes once on day 1
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1

====Supportive medications====
*[[Dexamethasone (Decadron)]] 8 mg PO the night before chemotherapy, the morning of day 1, 1 hour before chemotherapy, the night of day 1, the morning of day 2, and the evening of day 2 (6 total doses)
*[[Dexamethasone (Decadron)]] 20 mg IV before [[Cisplatin (Platinol)]] and 8 hours after [[Cisplatin (Platinol)]]
*[[Ondansetron (Zofran)]] 8 mg IV before [[Cisplatin (Platinol)]], 4 hours after [[Cisplatin (Platinol)]], and 8 hours after [[Cisplatin (Platinol)]]
*"Hydration was administered in a standard manner"

'''21-day cycles'''

===References===
# '''V-325:''' Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005 Aug 20;23(24):5660-7. [http://jco.ascopubs.org/content/23/24/5660.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16110025 PubMed]
# Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [http://jco.ascopubs.org/content/25/22/3217.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17664469 PubMed]

==Cisplatin & Fluorouracil {{#subobject:4d9936|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CF: '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
<br>FP: '''<u>F</u>'''luorouracil, '''<u>P</u>'''latinol (Cisplatin)
===Variant #1, 80/4000 {{#subobject:782e95|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/20/4/666.long Kang et al. 2009]
| style="background-color:#1a9851" |Phase III (C)
|[[#CX_2|CX]]
| style="background-color:#eeee01" |Non-inferior PFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext Bang et al. 2010 (ToGA)]
| style="background-color:#1a9851" |Phase III (C)
|[[#CF_.26_Trastuzumab|CF & Trastuzumab]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://academic.oup.com/annonc/article/28/9/2142/4061259 Ajani et al. 2017 (DIGEST)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_S-1|CS]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients in '''ToGA''' had overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation.''

''ToGA Patients: 100% adenocarcinoma (19% gastroesophageal junction, 81% gastric). 10% with ECOG of 2.''

''AVAGAST: this reigmen was for patients unable to take oral medications.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 4000 mg/m<sup>2</sup>)

====Supportive medications====
*Some protocols: "Hyperhydration" for [[Cisplatin (Platinol)]]

'''21-day cycle for up to 6 cycles (ToGA & AVAGAST) or 8 cycles (DIGEST)'''
====Subsequent treatment====
*AVAGAST: [[#Capecitabine_monotherapy_2|Capecitabine maintenance]]

===Variant #2, 100/4000 {{#subobject:16f88f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ar.iiarjournals.org/content/26/5B/3877.long Duffour et al. 2006 (FFCD 9404)]
| style="background-color:#1a9851" |Phase III (C)
|[[#FLP|FLP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 60 minutes once on day 1 or 2
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycles'''

===Variant #3, 100/4000, split-dose cisplatin {{#subobject:16f18e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/21/1/54.long Ohtsu et al. 2003 (JCOG 9205)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Fluorouracil_monotherapy|Fluorouracil]]
| style="background-color:#1a9850" |Superior PFS
|-
|2. [[#UFTM|UFTM]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Study included patients with PFS of 2 (9.6%)'' 

====Chemotherapy====
*[[Cisplatin (Platinol)]] 20 mg/m<sup>2</sup> IV over 30 minutes once per day on days 1 to 5
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycle for up to 6 cycles'''

===Variant #4, 100/5000 {{#subobject:10f0c6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/24/31/4991.long Van Cutsem et al. 2006 (V325 Study Group)]
| style="background-color:#1a9851" |Phase III (C)
|[[#DCF|DCF]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://annonc.oxfordjournals.org/content/19/8/1450.long Dank et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|[[#FOLFIRI|IF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/10.1200/JCO.2009.25.4706 Ajani et al. 2010 (FLAGS)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_S-1|CS]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Van Cutsem et al Patients: 100% adenocarcinoma histology (22% Esophagogastric junction, 88% gastric origin). 97% with metastatic disease. 1% with Karnosky PS of 70.'' 

''Dank et al Patients: 100% adenocarcinoma histology (20% Esophagogastric junction, 80% gastric origin). 96% with metastatic disease. 1% with Karnofsky PS of 70.'' 

====Chemotherapy====
*[[Cisplatin (Platinol)]] 100 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1, '''given first'''
*[[Fluorouracil (5-FU)]] 1000 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1, '''given second''' (total dose per cycle: 5000 mg/m<sup>2</sup> )

====Supportive medications====
*As described in Dank et al. 2008:
*"Hyperhydration" for 2 to 3 days with each infusion
*[[Ondansetron (Zofran)]] IV for antiemetic prophylaxis
*[[Dexamethasone (Decadron)]] IV for antiemetic prophylaxis, then PO for 2 to 3 days
*[[Metoclopramide (Reglan)]] for antiemetic prophylaxis
*[[Filgrastim (Neupogen)]] (dose not specified) SC once per day, starting on day 4, to be continued until ANC greater than 1000/uL for grade 3 to 4 neutropenia, febrile neutropenia, or neutropenic infection
*[[Atropine (Atropen)]] prn cholinergic symptoms 
*[[Loperamide (Imodium)]] prn delayed diarrhea

'''28-day cycles'''
===References===
# '''JCOG 9205:''' Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; Japan Clinical Oncology Group Study (JCOG9205). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. [http://jco.ascopubs.org/content/21/1/54.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506170 PubMed]
# '''FFCD 9404:''' Duffour J, Bouché O, Rougier P, Milan C, Bedenne L, Seitz JF, Buecher B, Legoux JL, Ducreux M, Vetter D, Raoul JL, François E, Ychou M. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Res. 2006 Sep-Oct;26(5B):3877-83. [http://ar.iiarjournals.org/content/26/5B/3877.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17094417 PubMed]
# '''V325 Study Group:''' Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006 Nov 1;24(31):4991-7. [http://jco.ascopubs.org/content/24/31/4991.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17075117 PubMed]
# Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol. 2008 Aug;19(8):1450-7. Epub 2008 Jun 16. [http://annonc.oxfordjournals.org/content/19/8/1450.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18558665 PubMed]
# Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. [http://annonc.oxfordjournals.org/content/20/4/666.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19153121 PubMed]
# '''FLAGS:''' Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010 Mar 20;28(9):1547-53. Epub 2010 Feb 16. [http://ascopubs.org/doi/10.1200/JCO.2009.25.4706 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20159816 PubMed]
# '''ToGA:''' Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20728210 PubMed]
# '''AVAGAST:''' Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2236 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21844504 PubMed]
# '''DIGEST:''' Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 1;28(9):2142-2148. [https://academic.oup.com/annonc/article/28/9/2142/4061259 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911091 PubMed]

==Cisplatin & S-1 {{#subobject:252c51|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CS: '''<u>C</u>'''isplatin & '''<u>S</u>'''-1
<br>SP: '''<u>S</u>'''-1 & '''<u>P</u>'''latinol (Cisplatin)
===Variant #1, q3wk ("SP3") {{#subobject:4ff7cf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/26/10/2097/144476 Ryu et al. 2015 (SOS)]
| style="background-color:#1a9851" |Phase III (E)
|SP5
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Tegafur, gimeracil, oteracil (S-1)]] 40 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycles'''

===Variant #2, q4wk {{#subobject:03b3c4|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/28/9/2142/4061259 Ajani et al. 2017 (DIGEST)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Fluorouracil_3|CF]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm of a study where the primary endpoint was not met. Included because CS has been shown to be superior in comparison to other regimens (see above).''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 75 mg/m<sup>2</sup> IV over 1 to 3 hours once on day 1
*[[Tegafur, gimeracil, oteracil (S-1)]] 25 mg/m<sup>2</sup> PO twice per day on days 1 to 21

'''28-day cycles'''

===Variant #3, q5wk ("SP5") {{#subobject:cdcc15|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70035-4/fulltext Koizumi et al. 2008 (SPIRITS)]
| style="background-color:#1a9851" |Phase III (E)
|[[#S-1_monotherapy_2|S-1]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://academic.oup.com/annonc/article/26/1/141/2802628 Yamada et al. 2014 (G-SOX)]
| style="background-color:#1a9851" |Phase III (C)
|SOX
| style="background-color:#eeee01" |Non-inferior PFS
|-
|[https://academic.oup.com/annonc/article/26/10/2097/144476 Ryu et al. 2015 (SOS)]
| style="background-color:#1a9851" |Phase III (C)
|SP3
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00553-7/fulltext Fujitani et al. 2016 (REGATTA)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.77.8613 Ishigami et al. 2018 (PHOENIX-GC)]
| style="background-color:#1a9851" |Phase III (C)
|IV/IP Paclitaxel & S-1
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
''Note: in REGATTA, there was no difference in outcome amongst patients who did or did not undergo surgery.'' 

''Inclusion criteria for REGATTA included the presence of a single non-curable factor (ex: hepatic, peritoneal, and para-aortic mets), see link for further details''

''SPIRITS trial included patients with ECOG of 2 (3% of patients)''

''Inclusion criteria for PHOENIX-GC included patients with peritoneal metastasis who had received less than or equal to 2 months of prior chemotherapy without disease progression, see link for further details''
====Preceding treatment====
*REGATTA: Non-laparoscopic [[Surgery#Gastrectomy|gastrectomy]] with D1 lymphadenectomy versus no surgery; chemotherapy began within 8 weeks of surgery
====Chemotherapy====
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 8
*[[Tegafur, gimeracil, oteracil (S-1)]] as follows:
**BSA less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 21
**BSA at least 1.25 m<sup>2</sup> and less than 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 21
**BSA 1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 21

'''35-day cycles'''

===References===
# '''SPIRITS:''' Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70035-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18282805 PubMed]
# '''G-SOX:''' Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015 Jan;26(1):141-8. Epub 2014 Oct 14. [https://academic.oup.com/annonc/article/26/1/141/2802628 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25316259 PubMed]
# '''SOS:''' Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK; SOS study investigators. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). Ann Oncol. 2015 Oct;26(10):2097-101. Epub 2015 Jul 27. [https://academic.oup.com/annonc/article/26/10/2097/144476 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26216386 PubMed]
# '''REGATTA:''' Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016 Mar;17(3):309-18. Epub 2016 Jan 26. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00553-7/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26822397 PubMed]
# '''DIGEST:''' Ajani JA, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A, Otchenash N, Alsina M, Lazarev S, Feliu J, Elme A, Esko V, Abdalla K, Verma U, Benedetti F, Aoyama T, Mizuguchi H, Makris L, Rosati G; DIGEST Study Group. A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017 Sep 1;28(9):2142-2148. [https://academic.oup.com/annonc/article/28/9/2142/4061259 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28911091 PubMed]
# '''PHOENIX-GC:''' Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y, Amagai K, Kadowaki S, Miwa H, Yamaguchi H, Yamaguchi T, Miyaji T, Kitayama J. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. Epub 2018 May 10. [http://ascopubs.org/doi/full/10.1200/JCO.2018.77.8613 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29746229 PubMed]

==CLF {{#subobject:b913d6|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CLF: '''<u>C</u>'''isplatin, '''<u>L</u>'''eucovorin, '''<u>F</u>'''luorouracil
<br>FLP: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>P</u>'''latinol (Cisplatin)
===Variant #1 {{#subobject:beef19|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/9/1435.long Al-Batran et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|[[#OLF|FLO]]
| style="background-color:#fee08b" |Might have inferior PFS
|-
|}
''Note: In contrast to the original reference, some guidelines list 5-FU as being given every 2 weeks rather than the schedule below.''

''Patients: 100% adenocarcinoma histology (20% gastroesophageal junction, 80% gastric'').
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43
*[[Fluorouracil (5-FU)]] 2000 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, 29, 36 (total dose per cycle: 12,000 mg/m<sup>2</sup>)

====Supportive medications====
*Up to 3 liters normal saline as hydration with [[Cisplatin (Platinol)]]
*Antiemetic medications per "local protocols"

'''8-week cycles'''

===Variant #2 {{#subobject:34890|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/21/4319.long Bouché et al. 2004 (FFCD 9803)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|1. [[Esophageal_cancer#Fluorouracil_.26_Folinic_acid|LV5FU2]]<br> 2. [[Esophageal_cancer#FOLFIRI|LV5FU2 & Irinotecan]]
| style="background-color:#d3d3d3" |Not powered to draw conclusions
|-
|}
''Note: the primary reference said every cycle was 15 days, but also said that medications were given every 14 days, so the assumption was made that this more regular schedule was used.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 50 mg/m<sup>2</sup> IV over 60 minutes once on either day 1 or 2
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Fluorouracil (5-FU)]] 400 mg/m<sup>2</sup> IV bolus once on day 1, then 1200 mg/m<sup>2</sup> IV continuous infusion over 22 hours (total dose per cycle: 1600 mg/m<sup>2</sup>)

====Supportive medications====
*1 liter hydration over 3 hours before and after [[Cisplatin (Platinol)]]
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] IV before [[Cisplatin (Platinol)]]
*[[Methylprednisolone (Solumedrol)]] 120 mg IV 10 minutes before [[Cisplatin (Platinol)]]
*Oral antiemetics and corticosteroids from days 2 to 5

'''14-day cycle for at least 4 cycles'''

===References===
# '''FFCD 9803:''' Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C; Fédération Francophone de Cancérologie Digestive Group. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol. 2004 Nov 1;22(21):4319-28. [http://jco.ascopubs.org/content/22/21/4319.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15514373 PubMed]
# Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. [http://jco.ascopubs.org/content/26/9/1435.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18349393 PubMed]

==CX {{#subobject:2bd34d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CX: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
<br>XP: '''<u>X</u>'''eloda (Capecitabine), '''<u>P</u>'''latinol (Cisplatin)
===Regimen {{#subobject:82b184|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/20/4/666.long Kang et al. 2009]
| style="background-color:#1a9851" |Phase III (E)
|[[#Cisplatin_.26_Fluorouracil_3|Cisplatin & Fluorouracil]]
| style="background-color:#eeee01" |Non-inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2236 Ohtsu et al. 2011 (AVAGAST)]
| style="background-color:#1a9851" |Phase III (C)
|CX & Bevacizumab
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70102-5/abstract Lordick et al. 2013 (EXPAND)]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine, Cisplatin, Cetuximab
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544634/ Shen et al. 2014 (AVATAR)]
| style="background-color:#1a9851" |Phase III (C)
|CX & Bevacizumab
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(14)00884-3/fulltext Kim et al. 2014]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine, Cisplatin, Simvastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097104/ Lu et al. 2018 (PAC-C)]
| style="background-color:#1a9851" |Phase III (C)
|Capecitabine & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|}
The following studies included patients with GE junction malignancy as well: 
* ''AVAGAST patients: 86% gastric and 14% GE junction. 5.4% of patients had an ECOG of 2.''
* ''EXPAND patients: 83% gastric, 5% GE junction and 16% unknown''
* ''Kim et al patients: 79% gastric, 16% GE junction and 5% unknown''

====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV over 2 hours once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
**EXPAND gave [[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day from the evening of day 1 to the morning of day 15 (28 doses per cycle)

====Supportive medications====
*Some protocols: "Hyperhydration" for [[Cisplatin (Platinol)]]

'''21-day cycles, varied duration (see below)'''
====Subsequent treatment====
*AVAGAST & AVATAR: after 6 cycles, [[#Capecitabine_monotherapy_2|capecitabine maintenance]]
*Kim et al. 2014: after 8 cycles, [[#Capecitabine_monotherapy_2|capecitabine maintenance]]

===References===
# Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. [http://annonc.oxfordjournals.org/content/20/4/666.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19153121 PubMed] content property of [http://hemonc.org HemOnc.org]
# '''AVAGAST:''' Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2236 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21844504 PubMed]
# '''EXPAND:''' Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie (AIO) and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):490-9. Epub 2013 Apr 15. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70102-5/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23594786 PubMed]
# '''AVATAR:''' Shen L, Li J, Xu J, Pan H, Dai G, Qin S, Wang L, Wang J, Yang Z, Shu Y, Xu R, Chen L, Liu Y, Yu S, Bu L, Piao Y. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). Gastric Cancer. 2015 Jan;18(1):168-76. Epub 2014 Feb 21. [https://link.springer.com/article/10.1007%2Fs10120-014-0351-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544634/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24557418 PubMed]
# Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. Epub 2014 Sep 15. [https://www.ejcancer.com/article/S0959-8049(14)00884-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25218337 PubMed]
# '''PAC-C:''' Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, Fan Q, Xu J, Xu N, Bai Y, Pan Y, Xu Q, Bai W, Xia L, Gao Y, Wang W, Shu Y, Shen L. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018 Sep;21(5):782-791. Epub 2018 Feb 27. [https://link.springer.com/article/10.1007%2Fs10120-018-0809-y link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097104/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29488121 PubMed]

==CX & Trastuzumab {{#subobject:7cbb79|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
CX & Trastuzumab: '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine), Trastuzumab
===Variant #1, 80/1600 {{#subobject:cdee6d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.6852 Shah et al. 2017 (HELOISE)]
| style="background-color:#1a9851" |Phase IIIb (C)
|CX & HD-Trastuzumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients had overexpression of HER2 protein by immunohistochemistry AND gene amplification by in-situ hybridisation.''

''Patients: 79% gastric, 21% GE junction, and all patients had an ECOG of 2''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 800 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1 (compared to HD-Trastuzumab at 10 mg/kg IV)
**Subsequent cycles: 6 mg/kg IV once on day 1

'''21-day cycle for up to 6 cycles; trastuzumab alone continued indefinitely'''

===Variant #2, 80/2000 {{#subobject:27adc6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext Bang et al. 2010 (ToGA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#CX|CX]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30481-9/fulltext Tabernero et al. 2018 (JACOB)]
| style="background-color:#1a9851" |Phase III (C)
|CX, Pertuzumab, Trastuzumab
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
''ToGA patients had overexpression of HER2 protein by immunohistochemistry OR gene amplification by fluorescence in-situ hybridisation.''

''ToGA patients: 81% gastric, 19% GE junction. 10% of patients with ECOG of 2.''
====Chemotherapy====
*[[Cisplatin (Platinol)]] 80 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Subsequent cycles: 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''ToGA:''' Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2961121-X/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20728210 PubMed]
# '''HELOISE:''' Shah MA, Xu RH, Bang YJ, Hoff PM, Liu T, Herráez-Baranda LA, Xia F, Garg A, Shing M, Tabernero J. HELOISE: Phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2-positive metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2017 Aug 1;35(22):2558-2567. Epub 2017 Jun 2.[http://ascopubs.org/doi/full/10.1200/JCO.2016.71.6852 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28574779 PubMed]
# '''JACOB:''' Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018 Oct;19(10):1372-1384. Epub 2018 Sep 11. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30481-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30217672 PubMed]

==ECF {{#subobject:6325cb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECF: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>F</u>'''luorouracil
===Regimen {{#subobject:e5ede0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://annonc.oxfordjournals.org/content/5/7/609.long Findlay et al. 1994]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/10.1200/JCO.1997.15.1.261 Webb et al. 1997]
| style="background-color:#1a9851" |Phase III (E)
|[[Gastric_cancer_-_historical#FAMTX|FAMTX]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://jco.ascopubs.org/content/20/8/1996.long Ross et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|[[#MCF|MCF]]
| style="background-color:#eeee01" |Seems to have noninferior OS
|-
|[http://jco.ascopubs.org/content/25/22/3217.long Roth et al. 2007]
| style="background-color:#1a9851" |Randomized Phase II (C)
|1. [[#Cisplatin_.26_Docetaxel_2|TC]]<br> 2. [[#DCF|TCF]]
| style="background-color:#d3d3d3" |Not reported
|-
| rowspan="3" |[https://www.nejm.org/doi/full/10.1056/NEJMoa073149 Cunningham et al. 2008 (REAL-2)]
| style="background-color:#1a9851" rowspan="3" |Phase III (C)
|1. [[#ECX_2|ECX]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|2. [[#EOF_2|EOF]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|3. [[#EOX_2|EOX]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''Findlay et al. Patients: all metastatic gastric cancer''

''Ross et al. Patients: adenocarcinoma, squamous carcinoma, or undifferentiated carcinoma histology, all advanced esophagogastric cancer.''

''Roth et al.  Patients: all metastatic gastric cancer'' 

''REAL-2 Patients: 35% esophageal, 25% gastroesophageal junction, 40% gastric. 11% ECOG PS of 2.'' 

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 4 hours once on day 1
*[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 21 days, started on day 1 (total dose per cycle: 4200 mg/m<sup>2</sup>)

====Supportive medications====
*(varied depending on reference):
*3 liters per day "hyperhydration"
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] for emesis prophylaxis
*Growth factor support allowed, such as with [[Filgrastim (Neupogen)]]
*Ross et al. 2002 & Cunningham et al. 2008 used [[Warfarin (Coumadin)]] 1 mg PO once per day for catheter thrombosis prophylaxis

'''21-day cycle for up to 8 cycles'''

===References===
# Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish T, Nicolson V, Nash A, Sacks N, Ford H, Carter R, Hill A. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol. 1994 Sep;5(7):609-16. [http://annonc.oxfordjournals.org/content/5/7/609.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7993836 PubMed]
# Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261-7. [http://ascopubs.org/doi/10.1200/JCO.1997.15.1.261 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8996151 PubMed]
## '''Update:''' Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, Joffe JK, Mackean M, Mansi J, Leahy M, Hill A, Oates J, Rao S, Nicolson M, Hickish T. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999 Apr;80(1-2):269-72. [https://www.nature.com/articles/6690350 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363002/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/10390007 PubMed]
# Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, Price T, Anderson H, Iveson T, Hickish T, Lofts F, Norman A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002 Apr 15;20(8):1996-2004. [http://jco.ascopubs.org/content/20/8/1996.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11956258 PubMed]
# Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Köberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. [http://jco.ascopubs.org/content/25/22/3217.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17664469 PubMed]
# '''REAL-2:''' Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008 Jan 3;358(1):36-46. [https://www.nejm.org/doi/full/10.1056/NEJMoa073149 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18172173 PubMed]

==ECX {{#subobject:36cac7|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
ECX: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>X</u>'''eloda (Capecitabine)
<br>ECC: '''<u>E</u>'''pirubicin, '''<u>C</u>'''isplatin, '''<u>C</u>'''apecitabine
===Variant #1, continuous capecitabine {{#subobject:f0efc0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30566-1/fulltext Catenacci et al. 2017 (RILOMET-1)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|ECX & Rilotumumab
| style="background-color:#1a9850" |Superior OS
|-
|}
''Patients had unresectable or metastatic MET-positive gastric or gastro-esophageal junction cancer.''

''Patients: ~80% gastric, 20% GE junction and 10% distal esophageal''
====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV once on day 1
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV once on day 1
*[[Capecitabine (Xeloda)]] 625 mg/m<sup>2</sup> PO twice per day

'''21-day cycle for up to 10 cycles'''

===Variant #2, intermittent capecitabine {{#subobject:f0efc0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(10)00731-8/fulltext Konings et al. 2010]
| style="background-color:#1a9851" |Randomized Phase II (C)
|ECC & Pravastatin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients: 6.6% of  patients had an ECOG of 2''

====Chemotherapy====
*[[Epirubicin (Ellence)]] 50 mg/m<sup>2</sup> IV bolus once on day 1, '''given first'''
*[[Cisplatin (Platinol)]] 60 mg/m<sup>2</sup> IV over 3 hours once on day 1, '''given second'''
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycle for up to 6 cycles'''

===References===
# Konings IR, van der Gaast A, van der Wijk LJ, de Jongh FE, Eskens FA, Sleijfer S. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer. 2010 Dec;46(18):3200-4. Epub 2010 Aug 18. [https://www.ejcancer.com/article/S0959-8049(10)00731-8/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20727735 PubMed]
# '''RILOMET-1:''' Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, Tejani MA, Udrea AA, Tehfe M, De Vita F, Turkington C, Tang R, Ang A, Zhang Y, Hoang T, Sidhu R, Cunningham D. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1467-1482. Epub 2017 Sep 25. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30566-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28958504 PubMed]

==Fluorouracil monotherapy {{#subobject:588907|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, CI {{#subobject:3289d8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/21/1/54.long Ohtsu et al. 2003 (JCOG 9205)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#Cisplatin_.26_Fluorouracil_3|FP]]
| style="background-color:#d73027" |Inferior PFS
|-
|2. [[#UFTM|UFTM]]
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70259-1/fulltext Boku et al. 2009 (JCOG 9912)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. Cisplatin & Irinotecan
| style="background-color:#fee08b" |Might have inferior OS
|-
|2. [[#S-1_monotherapy_2|S-1]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|[https://academic.oup.com/jjco/article/43/10/972/851849 Shirao et al. 2013 (JCOG 0106)]
|style="background-color:#1a9851" |Phase III (C)
|MF
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''JCOG 9205 included patients with PFS of 2 (9.6%)''

====Chemotherapy====
*[[Fluorouracil (5-FU)]] 800 mg/m<sup>2</sup>/day IV continuous infusion over 120 hours, started on day 1 (total dose per cycle: 4000 mg/m<sup>2</sup>)

'''28-day cycles'''

===Variant #2, intermittent {{#subobject:27a992|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jama/fullarticle/397816 Cullinan et al. 1985]
| style="background-color:#1a9851" |Phase III (E)
|1. FA<br> 2. [[Gastric_cancer_-_historical#FAM|FAM]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is an experimental arm that did not meet its primary endpoint; included here because it represents a de-escalation strategy.''
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 500 mg/m<sup>2</sup> IV once per day on days 1 to 5

'''28-day cycle for 2 cycles, then 35-day cycles'''

===Variant #3, PVI {{#subobject:d98c9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article/13/10/1568/167797 Tebbutt et al. 2002]
|style="background-color:#1a9851" |Phase III (C)
|5-FU & Mitomycin
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 300 mg/m<sup>2</sup>/day IV continuous infusion

'''Continuous for up to 24 weeks'''

===References===
# Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. [https://jamanetwork.com/journals/jama/fullarticle/397816 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2579257 PubMed]
# Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, Harper P, Maisey N, Mochlinski K, Prior Y, Hill M. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002 Oct;13(10):1568-75. [https://academic.oup.com/annonc/article/13/10/1568/167797 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377644 PubMed]
# '''JCOG 9205:''' Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; Japan Clinical Oncology Group Study (JCOG9205). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. [http://jco.ascopubs.org/content/21/1/54.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506170 PubMed]
# '''JCOG 9912:''' Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Epub 2009 Oct 7. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70259-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19818685 PubMed]
# '''JCOG 0106:''' Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, Nasu J, Denda T, Hamamoto Y, Takashima A, Fukuda H, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Randomized Phase III study of 5-fluorouracil continuous infusion vs sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin Oncol. 2013 Oct;43(10):972-80. Epub 2013 Sep 7. [https://academic.oup.com/jjco/article/43/10/972/851849 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24014884 PubMed]

==Fluorouracil, Folinic acid, Mitomycin {{#subobject:a4ca9d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:672a28|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.karger.com/Article/Abstract/64319 Hofheinz et al. 2002]
| style="background-color:#ffffbe" |Phase II, <20 pts in this subgroup
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours once per day on days 1, 8, 15, 22, 29, 36
*[[Folinic acid (Leucovorin)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36
*[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 22

'''56-day cycle for 2 cycles'''

===References===
# Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer: a phase II study. Onkologie. 2002 Jun;25(3):255-60. [http://www.karger.com/Article/Abstract/64319 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12119460 PubMed]

==Irinotecan monotherapy {{#subobject:41e063|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:9fb427|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007%2Fs10620-005-3038-2 Enzinger et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m<sup>2</sup> IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable."''

''Study included patients with GE junction and distal esophageal malignancy as well (~59% gastric, 9% GEJ and 33% distal esophagus)''

''Regimen showed a 14% response rate and 53% disease control rate.''
====Chemotherapy====
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 15, 22

'''42-day cycles'''

===References===
# Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. [http://link.springer.com/article/10.1007%2Fs10620-005-3038-2 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16416165 PubMed]

==OLF {{#subobject:98b4fa|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
OLF: '''<u>O</u>'''xaliplatin, '''<u>L</u>'''eucovorin, '''<u>F</u>'''luorouracil
<br>FLO: '''<u>F</u>'''luorouracil, '''<u>L</u>'''eucovorin, '''<u>O</u>'''xaliplatin
===Regimen {{#subobject:3d7273|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/9/1435.long Al-Batran et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|[[#CLF|FLP]]
| style="background-color:#d9ef8b" |Might have superior PFS
|-
|}
''Patients: 100% adenocarcinoma histology (20% esophagogastric junction, 80% gastric'').

====Chemotherapy====
*[[Oxaliplatin (Eloxatin)]] 85 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43
*[[Folinic acid (Leucovorin)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 15, 29, 43
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours, started on days 1, 15, 29, 43 (total dose per cycle: 10,400 mg/m<sup>2</sup>)

====Supportive medications====
*Antiemetic medications per "local protocols"

'''8-week cycles'''

===References===
# Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E; Arbeitsgemeinschaft Internistische Onkologie. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008 Mar 20;26(9):1435-42. [http://jco.ascopubs.org/content/26/9/1435.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18349393 PubMed]

==S-1 monotherapy {{#subobject:a12a2a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, BSA-based {{#subobject:86c009|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70259-1/fulltext Boku et al. 2009 (JCOG 9912)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. Cisplatin & Irinotecan
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[#Fluorouracil_monotherapy|5-FU]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
====Chemotherapy====
*[[Tegafur, gimeracil, oteracil (S-1)]] 40 mg/m<sup>2</sup> PO twice per day on days 1 to 28

'''42-day cycles'''

===Variant #2, weight-based {{#subobject:f90b1b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70035-4/fulltext Koizumi et al. 2008 (SPIRITS)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Cisplatin_.26_S-1|Cisplatin & S-1]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056989/ Narahara et al. 2011 (TOP-002)]
| style="background-color:#1a9851" |Phase III (C)
|IRIS
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ Koizumi et al. 2013 (START)]
| style="background-color:#1a9851" |Phase III (C)
|Docetaxel & S-1
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ejcancer.com/article/S0959-8049(16)32267-5/fulltext Yoshino et al. 2016 (JFMC36-0701)]
| style="background-color:#1a9851" |Phase III (C)
|Lentinan & S-1
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Chemotherapy====
*[[Tegafur, gimeracil, oteracil (S-1)]] as follows:
**BSA less than 1.25 m<sup>2</sup>: 40 mg PO twice per day on days 1 to 28
**BSA between 1.25 and 1.5 m<sup>2</sup>: 50 mg PO twice per day on days 1 to 28
**BSA 1.5 m<sup>2</sup> or more: 60 mg PO twice per day on days 1 to 28

'''42-day cycles'''
===References===
# '''SPIRITS:''' Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008 Mar;9(3):215-21. Epub 2008 Feb 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70035-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18282805 PubMed]
# '''JCOG 9912:''' Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009 Nov;10(11):1063-9. Epub 2009 Oct 7. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(09)70259-1/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19818685 PubMed]
# '''TOP-002:''' Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011 Mar;14(1):72-80. Epub 2011 Feb 23. [https://link.springer.com/article/10.1007%2Fs10120-011-0009-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056989/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21340666 PubMed]
# '''START:''' Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, Hosaka H, Tsuji A, Takagane A, Inokuchi M, Tanabe K, Okuno T, Ogura M, Yoshida K, Takeuchi M, Nakajima T; JACCRO and KCSG Study Group. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28. Epub 2013 Dec 24. [https://link.springer.com/article/10.1007%2Fs00432-013-1563-5 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895196/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24366758 PubMed]
# '''JFMC36-0701:''' Yoshino S, Nishikawa K, Morita S, Takahashi T, Sakata K, Nagao J, Nemoto H, Murakami N, Matsuda T, Hasegawa H, Shimizu R, Yoshikawa T, Osanai H, Imano M, Naitoh H, Tanaka A, Tajiri T, Gochi A, Suzuki M, Sakamoto J, Saji S, Oka M. Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). Eur J Cancer. 2016 Sep;65:164-71. Epub 2016 Aug 5. [https://www.ejcancer.com/article/S0959-8049(16)32267-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27501505 PubMed]

==UFTM {{#subobject:96e8bf|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
UFTM: '''<u>UFT</u>''' (Tegafur and uracil) & '''<u>M</u>'''itomycin 

===Regimen {{#subobject:3a603b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/21/1/54.long Ohtsu et al. 2003 (JCOG 9205)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Fluorouracil_monotherapy|Fluorouracil]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. [[#Cisplatin_.26_Fluorouracil_3|FP]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Study included patients with PFS of 2 (9.6%)''

====Chemotherapy====
*[[Tegafur and uracil (UFT)]] 375 mg/m<sup>2</sup>/day PO divided into two doses given twice per day
*[[Mitomycin (Mutamycin)]] 5 mg/m<sup>2</sup> IV once per week
**"Mitomycin was interrupted for 1 month after patients received a total dose of 60 mg."

'''Continued indefinitely'''

===References===
# '''JCOG 9205:''' Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; Japan Clinical Oncology Group Study (JCOG9205). Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol. 2003 Jan 1;21(1):54-9. [http://jco.ascopubs.org/content/21/1/54.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12506170 PubMed]

=Maintenance after first-line therapy=
==Capecitabine monotherapy {{#subobject:c6df5d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:878a56|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2236 Ohtsu et al. 2011 (AVAGAST)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|[https://www.ejcancer.com/article/S0959-8049(14)00884-3/fulltext Kim et al. 2014]
| style="background-color:#91cf61" |Non-randomized portion of RCT
|-
|}
''Ohtsu et al patients: 86% gastric and 14% GEJ.  5.4% of patients had an ECOG of 2.''

''Kim et al patients: 79% gastric, 5% GEJ, and 16% unknown. 2% of patients had an ECOG of 2.''
====Preceding treatment====
*AVAGAST: [[#CX_2|CX]] x 6
*Kim et al. 2014: [[#CX_2|CX]] x 8
====Chemotherapy====
*[[Capecitabine (Xeloda)]] 1000 mg/m<sup>2</sup> PO twice per day on days 1 to 14

'''21-day cycles'''
===References===
# Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct 20;29(30):3968-76. Epub 2011 Aug 15. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.2236 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21844504 PubMed]
# Kim ST, Kang JH, Lee J, Park SH, Park JO, Park YS, Lim HY, Hwang IG, Lee SC, Park KW, Lee HR, Kang WK. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014 Nov;50(16):2822-30. Epub 2014 Sep 15. [https://www.ejcancer.com/article/S0959-8049(14)00884-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25218337 PubMed]

=Metastatic or locally advanced disease, subsequent lines of therapy=
==Best supportive care==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(11)00396-0/abstract Thuss-Patience et al. 2011]
| style="background-color:#1a9851" |Phase III (C)
|[[#Irinotecan_monotherapy_2|Irinotecan]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://jco.ascopubs.org/content/30/13/1513.full Kang et al. 2012]
| style="background-color:#1a9851" |Phase III (C)
|1. [[#Docetaxel_monotherapy|Docetaxel]]<br> 2. [[#Irinotecan_monotherapy_2|Irinotecan]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext Ford et al. 2014 (COUGAR-02)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Docetaxel_monotherapy|Docetaxel]]
| style="background-color:#d73027" |Inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.48.3552 Ohtsu et al. 2013 (GRANITE-1)]
| style="background-color:#1a9851" |Phase III (C)
|Everolimus
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''No active antineoplastic treatment. Used as a comparator arm and here for reference purposes only.''

''Thuss-Patience et al. patients: ~58% gastric, 43% GEJ. 21% of patients had an  ECOG of 2.''

''GRANITE-1 study patients: 29% had GEJ involvement. 7.9% of patients had an ECOG of 2.''

===References===
# Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. [https://www.ejcancer.com/article/S0959-8049(11)00396-0/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21742485 PubMed]
# Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. [http://jco.ascopubs.org/content/30/13/1513.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22412140 PubMed]
# '''COUGAR-02:''' Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. Epub 2013 Dec 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24332238 PubMed]
# '''GRANITE-1:''' Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, Sahmoud T, Shen L, Yeh KH, Chin K, Muro K, Kim YH, Ferry D, Tebbutt NC, Al-Batran SE, Smith H, Costantini C, Rizvi S, Lebwohl D, Van Cutsem E. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013 Nov 1;31(31):3935-43. Epub 2013 Sep 16. [http://ascopubs.org/doi/full/10.1200/JCO.2012.48.3552 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/24043745 PubMed]

==Docetaxel monotherapy {{#subobject:4f3230|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1,  60 mg/m<sup>2</sup> {{#subobject:577cd6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/13/1513.full Kang et al. 2012]
| style="background-color:#1a9851" |Phase III (E)
|[[#Best_supportive_care|Best supportive care]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 60 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===Variant #2,  75 mg/m<sup>2</sup> {{#subobject:3b4816|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext Ford et al. 2014 (COUGAR-02)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Best_supportive_care|Best supportive care]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30111-0/fulltext Thuss-Patience et al. 2017 (GATSBY)]
| style="background-color:#1a9851" |Phase III (C)
|T-DM1
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients in GATSBY had HER2-positive disease. Study patients could only have been treated by one other regimen and could not have been exposed to anthracyclines''

''Patients: 68% gastric, 32% GEJ''
====Chemotherapy====
*[[Docetaxel (Taxotere)]] 75 mg/m<sup>2</sup> IV once on day 1

'''21-day cycle for up to 6 cycles (COUGAR-02) or indefinitely (GATSBY)'''

===References===
# Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. [http://jco.ascopubs.org/content/30/13/1513.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22412140 PubMed]
# '''COUGAR-02:''' Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, Swinson D, Falk S, Chau I, Cunningham D, Kareclas P, Cook N, Blazeby JM, Dunn JA; COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014 Jan;15(1):78-86. Epub 2013 Dec 10. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70549-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24332238 PubMed]
# '''GATSBY:''' Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 May;18(5):640-653. Epub 2017 Mar 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30111-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28343975 PubMed]

==Fluorouracil, Folinic acid, Mitomycin {{#subobject:b4ca9d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:672b28|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://www.karger.com/Article/Abstract/64319 Hofheinz et al. 2002]
| style="background-color:#ffffbe" |Phase II, <20 pts in this subgroup
|-
|}
====Chemotherapy====
*[[Fluorouracil (5-FU)]] 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours once per day on days 1, 8, 15, 22, 29, 36
*[[Folinic acid (Leucovorin)]] 500 mg/m<sup>2</sup> IV over 2 hours once per day on days 1, 8, 15, 22, 29, 36
*[[Mitomycin (Mutamycin)]] 10 mg/m<sup>2</sup> IV once per day on days 1 & 22

'''56-day cycle for 2 cycles'''

===References===
# Hofheinz RD, Hartung G, Samel S, Hochhaus A, Pichlmeier U, Post S, Hehlmann R, Queisser W. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer: a phase II study. Onkologie. 2002 Jun;25(3):255-60. [http://www.karger.com/Article/Abstract/64319 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12119460 PubMed]

==Irinotecan monotherapy {{#subobject:6df2c0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 125 mg/m<sup>2</sup>, 4 weeks out of 6 {{#subobject:9fb427|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 50%"|Study
!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
|-
|[http://link.springer.com/article/10.1007%2Fs10620-005-3038-2 Enzinger et al. 2005]
| style="background-color:#91cf61" |Phase II
|-
|}
''Note: In contrast to the primary references, some guidelines list a dosing schedule of 125 mg/m<sup>2</sup> IV once per day on days 1 & 8, with 21-day cycles. Enzinger et al. 2005 comment that "when irinotecan is used as a single-agent, a tri-weekly schedule may be preferable."''

''Study included patients with GE junction and distal esophageal malignancy as well (~59% gastric, 9% GE junction and 33% distal esophagus)''

''Regimen showed a 14% response rate and 53% disease control rate.'' 

====Chemotherapy====
*[[Irinotecan (Camptosar)]] 125 mg/m<sup>2</sup> IV over 90 minutes once per day on days 1, 8, 15, 22

'''42-day cycles'''

===Variant #2, 150 mg/m<sup>2</sup> q2wk {{#subobject:fa1ef9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/30/13/1513.full Kang et al. 2012]
| style="background-color:#1a9851" |Phase III (E)
|[[#Best_supportive_care|Best supportive care]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.48.5805 Hironaka et al. 2013 (WJOG 4007)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy|Paclitaxel]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ejcancer.com/article/S0959-8049(14)00093-8/fulltext Higuchi et al. 2014 (BIRIP)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Irinotecan
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[https://www.ejcancer.com/article/S0959-8049(15)00209-9/fulltext Nishikawa et al. 2015 (TRICS)]
| style="background-color:#1a9851" |Phase III (C)
|Cisplatin & Irinotecan
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/26/9/1916/189421 Tanabe et al. 2015 (JACCRO GC-05)]
| style="background-color:#1a9851" |Phase III (C)
|Irinotecan & S-1
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Hironaka et al patients: 3.7% patients with an ECOG PS of 2''

====Chemotherapy====
*[[Irinotecan (Camptosar)]] 150 mg/m<sup>2</sup> IV once on day 1

'''14-day cycles'''

===Variant #3, 300 mg/m<sup>2</sup> q3wk {{#subobject:c410d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
!Comparator
|-
|[http://annonc.oxfordjournals.org/content/24/6/1567.long Roy et al. 2013]
| style="background-color:#1a9851" |Randomized Phase II (C)
|1. [[#Docetaxel_monotherapy|Docetaxel]]<br> 2. Irinotecan liposome
|-
|}
''Study included patients with GE junction malignancy (77% gastric, 23% GE junction) and included patients with ECOG of 2''

====Chemotherapy====
*[[Irinotecan (Camptosar)]] 300 mg/m<sup>2</sup> IV over 90 minutes once on day 1

'''21-day cycles'''

===Variant #4, 350 mg/m<sup>2</sup> q3wk {{#subobject:160f2f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/S0959-8049(11)00396-0/fulltext Thuss-Patience et al. 2011]
| style="background-color:#1a9851" |Phase III (E)
|[[#Best_supportive_care|Best supportive care]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Thuss-Patience et al. included patients with GE junction malignancy (~58% gastric, 43% GE junction) and included patients with ECOG of 2''

====Chemotherapy====
*[[Irinotecan (Camptosar)]] as follows:
**Cycle 1: 250 mg/m<sup>2</sup> (maximum dose of 500 mg) IV over 30 minutes once on day 1
**Cycles 2 to 10 (depending on toxicity): 350 mg/m<sup>2</sup> IV over 30 minutes once on day 1

====Supportive medications====
*[[Atropine (Atropen)]] 0.25 mg SC before irinotecan as prophylaxis against cholinergic symptoms 
*[[:Category:Serotonin_5-HT3_antagonists|5-HT3 antagonist]] 
*[[Dexamethasone (Decadron)]]

'''21-day cycle for up to 10 cycles'''

===References===
# Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vincitore MM, Michelini AL, Mayer RJ, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. 2005 Dec;50(12):2218-23. [http://link.springer.com/article/10.1007%2Fs10620-005-3038-2 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16416165 PubMed]
# Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011 Oct;47(15):2306-14. [https://www.ejcancer.com/article/S0959-8049(11)00396-0/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21742485 PubMed]
# Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012 May 1;30(13):1513-8. Epub 2012 Mar 12. Erratum in: J Clin Oncol. 2012 Aug 20;30(24):3035. [http://jco.ascopubs.org/content/30/13/1513.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22412140 PubMed]
# Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [http://annonc.oxfordjournals.org/content/24/6/1567.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/23406728 PubMed]
# '''WJOG 4007:''' Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. [http://ascopubs.org/doi/full/10.1200/JCO.2012.48.5805 link to original artile] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24190112 PubMed]
# '''BIRIP:''' Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, Takeda Y, Moriwaki T, Amagai K, Sekikawa T, Sakuyama T, Kanda T, Sasaki T, Azuma M, Takahashi F, Takeuchi M, Koizumi W; Tokyo Cooperative Oncology Group, Tokyo, Japan. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014 May;50(8):1437-45. Epub 2014 Feb 20. [https://www.ejcancer.com/article/S0959-8049(14)00093-8/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24560487 PubMed]
# '''TRICS:''' Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, Yoshikawa T, Ishiguro T, Nakamura M, Morita S, Miyashita Y, Tsuburaya A, Sakamoto J, Tsujinaka T. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer. 2015 May;51(7):808-16. Epub 2015 Mar 18. [https://www.ejcancer.com/article/S0959-8049(15)00209-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25797356 PubMed]
# '''JACCRO GC-05:''' Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, Takagane A, Ohno T, Kawase T, Kochi M, Yoshida K, Kakeji Y, Ichikawa W, Chin K, Terashima M, Takeuchi M, Nakajima T; JACCRO GC-05 study group. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol. 2015 Sep;26(9):1916-22. Epub 2015 Jun 24. [https://academic.oup.com/annonc/article/26/9/1916/189421 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26109630 PubMed]

==Irinotecan liposomal monotherapy {{#subobject:9a99c8|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c50e15|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
|'''Comparator'''
|-
|[https://annonc.oxfordjournals.org/content/24/6/1567.long Roy et al. 2013]
| style="background-color:#1a9851" |Randomized Phase II (E)
|1. [[#Docetaxel_monotherapy|Docetaxel]]<br> 2. [[#Irinotecan_monotherapy|Irinotecan]]
|-
|}
====Chemotherapy====
*[[Irinotecan liposome (Onivyde)]] 120 mg/m<sup>2</sup> IV over 90 minutes once on day 1

'''21-day cycles'''

===References===
# Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 Jun;24(6):1567-73. Epub 2013 Feb 13. [https://annonc.oxfordjournals.org/content/24/6/1567.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23406728 PubMed]

==Nivolumab monotherapy {{#subobject:7011e1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:#f2fd8e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31827-5/fulltext Kang et al. 2017 (ATTRACTION-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834/ Janjigian et al. 2018 (CheckMate-032)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|}
''ATTRACTION-2 included patients with GE junction malignancy (82.6% gastric, 8.5% GE junction) and 12.3% of patients had a PD-L1 CPS score of at least 1''

====Immunotherapy====
*[[Nivolumab (Opdivo)]] 3 mg/kg IV once on day 1

'''14-day cycles'''

===References===
# '''ATTRACTION-2:''' Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31827-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28993052 PubMed]
# '''CheckMate-032:''' Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. Epub 2018 Aug 15. [http://ascopubs.org/doi/full/10.1200/JCO.2017.76.6212 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161834/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/30110194 PubMed]

==Paclitaxel monotherapy {{#subobject:2dcad9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 80 mg/m<sup>2</sup> weekly {{#subobject:0e8f41|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ar.iiarjournals.org/content/27/4C/2667.long Kodera et al. 2007 (CCOG0302)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30111-0/fulltext Thuss-Patience et al. 2017 (GATSBY)]
| style="background-color:#1a9851" |Phase III (C)
|T-DM1
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Patients had overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation''

''Study included patients with GE junction malignancy (68% gastric, 32% GE junction)''
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per week

'''Continued indefinitely'''

===Variant #2, 80 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:dd21e8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs10120-005-0351-6 Hironaka et al. 2006]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2012.48.5805 Hironaka et al. 2013 (WJOG 4007)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Irinotecan_monotherapy_2|Irinotecan]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2013.53.6136 Satoh et al. 2014 (TyTAN)]
| style="background-color:#1a9851" |Phase III (C)
|Lapatinib & Paclitaxel
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970420-6/fulltext Wilke et al. 2014 (RAINBOW)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Paclitaxel_.26_Ramucirumab|Paclitaxel & Ramucirumab]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|rowspan=2|[https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30219-9/fulltext Shitara et al. 2017 (ABSOLUTE)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. [[#Paclitaxel.2C_nanoparticle_albumin-bound_monotherapy|Weekly nab-Paclitaxel]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|2. nab-Paclitaxel q3wk
| style="background-color:#d9ef8b" |Might have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30682-4/fulltext Bang et al. 2017 (GOLD)]
| style="background-color:#1a9851" |Phase III (C)
|Olaparib & Paclitaxel
| style="background-color:#fee08b" |Might have inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31257-1/fulltext Shitara et al. 2018 (KEYNOTE-061)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Pembrolizumab_monotherapy|Pembrolizumab]]
| style="background-color:#fee08b" |Might have inferior OS
|-
|}
''Eligibility criteria for patients in RAINBOW included: "documented objective radiological or clinical disease progression during or within 4 months of the last dose of first-line platinum and fluoropyrimidine doublet with or without anthracycline." Patients in TyTAN had HER2-positive disease.''

''RAINBOW included patients with GE junction malignancy (79% gastric, 21% GE junction)''

''Satoh et al. patients: 98.5% gastric. 1.5 other''

''Hironaka et al patients: 3.7% patients with a PFS of 2''

====Chemotherapy====
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1, 8, 15

'''28-day cycles'''

===Variant #3, 175 mg/m<sup>2</sup> q3wk {{#subobject:a4bdf6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/annonc/article-abstract/29/5/1220/4846849 Kang et al. 2018 (DREAM)]
| style="background-color:#1a9851" |Phase III (C)
|DHP107
| style="background-color:#eeee01" |Non-inferior PFS
|-
|}
====Chemotherapy====
*[[Paclitaxel (Taxol)]] 175 mg/m<sup>2</sup> IV once on day 1

'''21-day cycles'''

===References===
# Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer. 2006;9(1):14-8. [https://link.springer.com/article/10.1007%2Fs10120-005-0351-6 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16557431 PubMed]
# '''CCOG0302:''' Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, Matsui T, Kojima H, Takase T, Ohashi N, Fujiwara M, Sakamoto J, Akimasa N; Chubu Clinical Cancer Group. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007 Jul-Aug;27(4C):2667-71. [http://ar.iiarjournals.org/content/27/4C/2667.long link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17695430 PubMed]
# '''WJOG 4007:''' Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013 Dec 10;31(35):4438-44. Epub 2013 Nov 4. [http://ascopubs.org/doi/full/10.1200/JCO.2012.48.5805 link to original artile] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24190112 PubMed]
# '''TyTAN:''' Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014 Jul 1;32(19):2039-49. Epub 2014 May 27. [http://ascopubs.org/doi/full/10.1200/JCO.2013.53.6136 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24868024 PubMed]
# '''RAINBOW:''' Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970420-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25240821 PubMed]
# '''ABSOLUTE:''' Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. [https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30219-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28404157 PubMed]
# '''GATSBY:''' Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017 May;18(5):640-653. Epub 2017 Mar 23. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30111-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28343975 PubMed]
# '''GOLD:''' Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Dec;18(12):1637-1651. Epub 2017 Nov 2. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30682-4/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29103871 PubMed]
# '''DREAM:''' Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018 May 1;29(5):1220-1226. [https://academic.oup.com/annonc/article-abstract/29/5/1220/4846849 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29438463 PubMed]
# '''KEYNOTE-061:''' Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. Epub 2018 Jun 4. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31257-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29880231 PubMed]

==Paclitaxel, nanoparticle albumin-bound monotherapy {{#subobject:8f6227|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fe2978|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30219-9/fulltext Shitara et al. 2017 (ABSOLUTE)]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|1. [[#Paclitaxel_monotherapy|Weekly Paclitaxel]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|2. nab-Paclitaxel q3wk
| style="background-color:#d3d3d3" |Not reported
|-
|}
====Chemotherapy====
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]] 100 mg/m<sup>2</sup> IV once per day on days 1, 8, 15

'''28-day cycles'''

===References===
# '''ABSOLUTE:''' Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, Ueda S, Yoshida K, Shimodaira H, Nishina T, Tsuda M, Kurokawa Y, Tamura T, Sasaki Y, Morita S, Koizumi W. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017 Apr;2(4):277-287. Epub 2017 Jan 19. [https://www.thelancet.com/journals/langas/article/PIIS2468-1253(16)30219-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28404157 PubMed]

==Paclitaxel & Ramucirumab {{#subobject:fdd93f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f66446|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
![[Overall response rate|'''ORR''']]
!Comparator
!Comparator [[Overall response rate|'''ORR''']]
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970420-6/fulltext Wilke et al. 2014 (RAINBOW)]
| style="background-color:#1a9851" |Phase III (E)
| style="background-color:#8c6bb1" |28% (95% CI 23-33%)
|[[#Paclitaxel_monotherapy|Paclitaxel]]
| style="background-color:#88419d; color:white " |16% (95% CI 13-20%)
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Eligibility criteria for patients in RAINBOW included: "documented objective radiological or clinical disease progression during or within 4 months of the last dose of first-line platinum and fluoropyrimidine doublet with or without anthracycline."''

''RAINBOW included patients with GE junction malignancy (79% gastric, 21% GE junction).''

====Chemotherapy====
*[[Ramucirumab (Cyramza)]] 8 mg/kg IV over 60 minutes once per day on days 1 & 15, '''given first'''
*[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15, '''given second'''

'''28-day cycles'''

===References===
# '''RAINBOW:''' Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224-35. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2970420-6/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25240821 PubMed]

==Pembrolizumab monotherapy {{#subobject:88c665|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:ac7d94|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885175/ Fuchs et al. 2018 (KEYNOTE-059)]
| style="background-color:#91cf61" |Phase II
|
|ORR: 12% (95% CI 8-16)
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31257-1/fulltext Shitara et al. 2018 (KEYNOTE-061)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Paclitaxel_monotherapy|Paclitaxel]]
| style="background-color:#d9ef8b" |Might have superior OS
|-
|}
''Both studies included patients with GE junction malignancy:''
* ''KEYNOTE-059: 48.3% gastric, 51.4% GE junction and 57.1% of patients had a PD-L1 CPS score of at least 1''

* ''KEYNOTE-061: 68.8% gastric, 31.2% GE junction and 66% of all patients receiving pembrolizumab had a PD-L1 CPS score of at least 1''

====Immunotherapy====
*[[Pembrolizumab (Keytruda)]] 200 mg IV once on day 1

'''21-day cycle for up to 35 cycles'''

===References===
<!-- # '''Abstract:''' Charles S. Fuchs, Toshihiko Doi, Raymond Woo-Jun Jang, Kei Muro, Taroh Satoh, Manuela Machado, ...Weijing Sun, Shadia Ibrahim Jalal, Manish A. Shah, Jean-Philippe Metges, Marcelo Garrido, Talia Golan, Mario Mandala, Zev A. Wainberg, Daniel V.T. Catenacci, Yung-Jue Bang, Jiangdian Wang, Minori Koshiji, Rita P. Dalal, Harry H. Yoon (2017). KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer. Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 4003-4003. [http://ascopubs.org/doi/full/10.1200/JCO.2017.35.15_suppl.4003 link to abstract] -->
# '''KEYNOTE-059:''' Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018 May 10;4(5):e180013. Epub 2018 May 10. [https://jamanetwork.com/journals/jamaoncology/fullarticle/2675013 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885175/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29543932 PubMed]
# '''KEYNOTE-061:''' Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo MD, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392(10142):123-133. Epub 2018 Jun 4. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31257-1/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29880231 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext Fuchs et al. 2013 (REGARD)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Ramucirumab_monotherapy|Ramucirumab]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019744/ Pavlakis et al. 2016 (INTEGRATE)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Regorafenib_monotherapy|Regorafenib]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31827-5/fulltext Kang et al. 2017 (ATTRACTION-2)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Nivolumab_monotherapy|Nivolumab]]
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30739-3/fulltext Shitara et al. 2018 (TAGS)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Trifluridine_and_tipiracil_monotherapy|Trifluridine/tipiracil]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''All studies included patients with GE junction malignancy:''
* ''REGARD: 75% gastric, 25% GE junction''
* ''INTEGRATE: 62% stomach or other, 38% GE junction''
* ''ATTRACTION-2: 82.6% gastric, 8.5% GE junction''
''Patients in '''REGARD''' previously had "disease progression within 4 months of the last dose of first-line platinum-containing or fluoropyrimidine-containing chemotherapy for metastatic disease, or within 6 months of the last dose of platinum-containing or fluoropyrimidine-containing adjuvant treatment."''

''No active antineoplastic treatment.''

===References===
# '''REGARD:''' Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3.[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24094768 PubMed]
# '''INTEGRATE:''' Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II trial. J Clin Oncol. 2016 Aug 10;34(23):2728-35. Epub 2016 Jun 20. [http://ascopubs.org/doi/full/10.1200/JCO.2015.65.1901 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019744/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27325864 PubMed]
# '''ATTRACTION-2:''' Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)31827-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28993052 PubMed]
# '''TAGS:''' Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov 1;19(11):1437-48. Epub 2018 Oct 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30739-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30355453 PubMed]

==Ramucirumab monotherapy {{#subobject:425b15|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:813cff|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!Study
![[Levels_of_Evidence#Evidence|Evidence]]
![[Overall response rate|'''ORR''']]
!Comparator
!Comparator [[Overall response rate|'''ORR''']]
![[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext Fuchs et al. 2013 (REGARD)]
| style="background-color:#1a9851" |Phase III (E)
| style="background-color:#6e016b; color:white " |3%
|[[#Placebo|Placebo]]
| style="background-color:#6e016b; color:white " |3%
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
''Patients in REGARD previously had "disease progression within 4 months of the last dose of first-line platinum-containing or fluoropyrimidine-containing chemotherapy for metastatic disease, or within 6 months of the last dose of platinum-containing or fluoropyrimidine-containing adjuvant treatment."''

''Study includes patients with GE junction malignancy (75% gastric, 25% GE junction).''
====Chemotherapy====
*[[Ramucirumab (Cyramza)]] 8 mg/kg IV over 60 minutes once on day 1

'''14-day cycles'''

===References===
# '''REGARD:''' Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2961719-5/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/24094768 PubMed]

==Regorafenib monotherapy {{#subobject:022ef0|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:5f203f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019744/ Pavlakis et al. 2016 (INTEGRATE)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
''INTEGRATE included patients with GEJ malignancy: 62% stomach or other, 38% GEJ''

====Chemotherapy====
*[[Regorafenib (Stivarga)]] 160 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# '''INTEGRATE:''' Pavlakis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalcberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): A multinational placebo-controlled phase II trial. J Clin Oncol. 2016 Aug 10;34(23):2728-35. Epub 2016 Jun 20. [http://ascopubs.org/doi/full/10.1200/JCO.2015.65.1901 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019744/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27325864 PubMed]

==Trifluridine and tipiracil monotherapy {{#subobject:938bf3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:cfc20c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30739-3/fulltext Shitara et al. 2018 (TAGS)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemotherapy====
*[[Trifluridine and tipiracil (Lonsurf)]] 35 mg/m<sup>2</sup> PO twice per day on days 1 to 5, 8 to 12

'''28-day cycles'''

===References===
# '''TAGS:''' Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris L, Ilson DH, Tabernero J. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Nov 1;19(11):1437-48. Epub 2018 Oct 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30739-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/30355453 PubMed]

[[Category:Gastric cancer regimens]]
[[Category:Disease-specific pages]]
[[Category:Gastrointestinal cancers]]
